Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.
WSC provides unique Financial Market research and analysis including Indexes, Stocks, ETFs, Currencies and Commodities. We are working to build a smarter consensus.
Ideas & Analysis are personal opinion and not investment advice.
Founder of stock screener with single click backtest ,
fav quote: "In God we trust; all others must bring data" W. Edwards Deming ,
linkedin profitle @ http://www.linkedin.com/profile/view?id=1383774&trk=tab_pro
Darcy Keith is an editor with Canada's Globe and Mail and has followed financial markets for 20 years. He was previously Yahoo Canada's senior finance editor, Canwest's national biz editor, and a correspondent for Knight-Ridder Financial News.
Mark Arbeter joined Standard & Poor’s in 1987. Mark became S&P’s chief technical analyst in 1995 and is now S&P Capital IQ's chief technical strategist. Mark is the Chairperson for the Market Technicians Association admission committee.